These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 8329573)
1. Factor VIII and DDAVP reverse the effect of recombinant desulphatohirudin (CGP 39393) on bleeding in the rat. Butler KD; Dolan SL; Talbot MD; Wallis RB Blood Coagul Fibrinolysis; 1993 Jun; 4(3):459-64. PubMed ID: 8329573 [TBL] [Abstract][Full Text] [Related]
2. The influence of infusions of 1-desamino-8-D-arginine vasopressin (DDAVP) in vivo on the anticoagulant effect of recombinant hirudin (CGP39393) in vitro. Ibbotson SH; Grant PJ; Kerry R; Findlay VS; Prentice CR Thromb Haemost; 1991 Jan; 65(1):64-6. PubMed ID: 1902596 [TBL] [Abstract][Full Text] [Related]
3. Haemostyptic effects of batroxobin with regard to hirudin treatment. Markwardt F; Kaiser B; Richter M Thromb Res; 1992 Dec; 68(6):475-82. PubMed ID: 1341058 [TBL] [Abstract][Full Text] [Related]
4. Biologic effects of recombinant hirudin (CGP 39393) in human volunteers. European Hirudin in Thrombosis Group. Verstraete M; Nurmohamed M; Kienast J; Siebeck M; Silling-Engelhardt G; Büller H; Hoet B; Bichler J; Close P J Am Coll Cardiol; 1993 Oct; 22(4):1080-8. PubMed ID: 8409044 [TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacology of intravenously administered recombinant desulfatohirudin (CGP 39393) in healthy volunteers. Marbet GA; Verstraete M; Kienast J; Graf P; Hoet B; Tsakiris DA; Silling-Engelhardt G; Close P J Cardiovasc Pharmacol; 1993 Sep; 22(3):364-72. PubMed ID: 7504125 [TBL] [Abstract][Full Text] [Related]
7. Effects of agents, used to treat bleeding disorders, on bleeding time prolonged by a very high dose of a direct thrombin inhibitor in anesthesized rats and rabbits. Elg M; Carlsson S; Gustafsson D Thromb Res; 2001 Feb; 101(3):159-70. PubMed ID: 11228339 [TBL] [Abstract][Full Text] [Related]
8. Direct thrombin inhibition with Rec-hirudin CGP 39393 as prophylaxis of thromboembolic complications after total hip replacement. Eriksson BI; Kälebo P; Ekman S; Lindbratt S; Kerry R; Close P Thromb Haemost; 1994 Aug; 72(2):227-31. PubMed ID: 7831657 [TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of recombinant hirudin (CGP 39 393) versus heparin in patients with stable angina undergoing coronary angioplasty. van den Bos AA; Deckers JW; Heyndrickx GR; Laarman GJ; Suryapranata H; Zijlstra F; Close P; Rijnierse JJ; Buller HR; Serruys PW Circulation; 1993 Nov; 88(5 Pt 1):2058-66. PubMed ID: 8222099 [TBL] [Abstract][Full Text] [Related]
10. DDAVP reduces bleeding during continued hirudin administration in the rabbit. Bove CM; Casey B; Marder VJ Thromb Haemost; 1996 Mar; 75(3):471-5. PubMed ID: 8701410 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of CGP 39393 as the anticoagulant in cardiopulmonary bypass operation in a dog model. Walenga JM; Koza MJ; Park SJ; Terrell MR; Pifarré R Ann Thorac Surg; 1994 Dec; 58(6):1685-9. PubMed ID: 7979736 [TBL] [Abstract][Full Text] [Related]
13. Effect of 1-deamino-8-D-arginine vasopressin on the prolonged bleeding time in chronic renal failure. Watson AJ; Keogh JA Nephron; 1982; 32(1):49-52. PubMed ID: 6817151 [TBL] [Abstract][Full Text] [Related]
14. Some objective considerations for the neutralization of the anticoagulant actions of recombinant hirudin. Fareed J; Walenga JM; Pifarre R; Hoppensteadt D; Koza M Haemostasis; 1991; 21 Suppl 1():64-72. PubMed ID: 1894198 [TBL] [Abstract][Full Text] [Related]
15. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada. CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466 [TBL] [Abstract][Full Text] [Related]
16. Investigation of activated prothrombin complex concentrate as potential hirudin antidote in animal models. Diehl KH; Römisch J; Hein B; Jessel A; Ronneberger H; Pâques EP Haemostasis; 1995; 25(4):182-92. PubMed ID: 7557657 [TBL] [Abstract][Full Text] [Related]
17. Shortening of bleeding time by 1-deamino-8-D-arginine vasopressin in various bleeding disorders. Kobrinsky NL; Israels ED; Gerrard JM; Cheang MS; Watson CM; Bishop AJ; Schroeder ML Lancet; 1984 May; 1(8387):1145-8. PubMed ID: 6144876 [TBL] [Abstract][Full Text] [Related]
18. Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery. Leadley RJ; Kasiewski CJ; Bostwick JS; Bentley R; McVey MJ; White FJ; Perrone MH; Dunwiddie CT Thromb Haemost; 1997 Oct; 78(4):1278-85. PubMed ID: 9364998 [TBL] [Abstract][Full Text] [Related]
19. Development of an anti-bleeding agent for recombinant hirudin induced skin bleeding in the pig. Dickneite G; Nicolay U; Friesen HJ; Reers M Thromb Haemost; 1998 Jul; 80(1):192-8. PubMed ID: 9684809 [TBL] [Abstract][Full Text] [Related]